AKEBIA THERAPEUTICS INC

Akebia Therapeutics’ stock slides to $0.56, raising doubts about its HIF drug pipeline, limited revenue, and strategic focus amid stronger biotech peers.

Akebia Therapeutics stock drops 40% m/m—investors face a steep decline in a niche HIF‑kidney drug, with no clear clinical or regulatory milestones yet.

Akebia Therapeutics’ stock slides 9% to $0.62, below its 200‑day average. The niche HIF kidney therapy company faces volatility but may rebound with new clinical milestones.